Skip to main content
. 2011 Nov 18;6(11):e27852. doi: 10.1371/journal.pone.0027852

Table 4. Properties of Anticoagulants.

Chemical Expression Clinical Dose Range(Prophylaxis)
UFH AT+UFHInline graphicAT-UFH 0.1 – 0.4 U/mLa
Xa+AT-UFH→Xa-AT+UFH
IXa+AT-UFH→IXa-AT+UFH
mIIa+AT-UFH→mIIa-AT+UFH
TF-VIIa+AT-UFH→TF-VIIa-AT+UFH
Va-Xa+AT-UFH→Va-Xa-AT+UFH
IIa+AT-UFH→IIa-AT+UFH
Fpx AT+FInline graphicAT-F 0.12 – 0.4 µMb
Xa+AT-F→Xa-AT+F
IXa+AT-F→IXa-AT+F
mIIa+AT-F→mIIa-AT+F
TF-VIIa+AT-F→TF-VIIa-AT+F
Va-Xa+AT-F→Va-Xa-AT+F
IIa+AT-F→IIa-AT+F
Rivaroxaban Xa+RInline graphicXa-R 0.02 – 0.31 µMc
Va-Xa+RInline graphicVa-Xa-R
DAPA IIa+DAPAInline graphicIIa-DAPA 0.6 – 1.8 µMd
mIIa+DAPAInline graphicmIIa-DAPA 0.08 – 0.39 µMe
mIIa-DAPA+Xa-Va→IIa-DAPA+Xa-Va
a

1U ≡ 170 nM functional heparin molecules; in blood, >90% of UFH may be unavailable for binding with AT [28], [45].

b

Fpx binds almost exclusively to AT in blood [34], [46].

c

Ctrough – Cmax (10 mg once daily): 5 – 8% free in plasma [47], [48].

d

Dose ranges for Argatroban, a structurally related reversible thrombin inhibitor in clinical use (KD = 20 nM) [49].

e

Ctrough – Cmax for Dabigatran (220 mg once daily), a reversible thrombin inhibitor (KD = 50 pM) [50], [51].